On March 6, 2026, Robinhood Ventures Fund I listed on the NYSE at $25.00 a share against a net asset value of $24.70. Fair value, more or less. Eleven weeks later it traded at $57.02. Retail buyers were paying roughly $1.90 for every dollar of private startups the fund actually held, on the logic that RVI was the only liquid way to own a slice of SpaceX, OpenAI, and Anthropic.
Then SpaceX went public on Nasdaq on June 12, and the scarcity that justified the premium stopped existing. RVI slid to $35 by mid-June, $26 by mid-July, and $24.81 by the end of the month. Anyone who bought the May peak was down more than 50% while the underlying portfolio, if anything, had gotten more valuable after its largest holding’s IPO.
On August 13, 2026, Robinhood did it again. Robinhood Ventures Fund II is a publicly traded closed-end fund that gives retail investors indirect exposure to roughly 80 private startups tied to Y Combinator, trading on the NYSE under the ticker RVII. It priced 8,000,000 shares at $25.00 and raised $225.5 million, according to Robinhood’s pricing announcement. It opened at $22.50, a 10% discount to the offer price, and closed the next session at $24.45.
Which raises the question a lot of people started typing into Google that week: can you actually invest in Y Combinator startups, and is a $25 ticker the right way to do it?
Last updated: August 2026
Quick answers
How do you invest in Y Combinator startups? There are five routes: buying shares of Robinhood Ventures Fund II (RVII) on the NYSE, backing individual companies on Regulation Crowdfunding platforms like Wefunder, joining an AngelList or FundersClub syndicate, buying secondaries on Forge or EquityZen, or becoming an LP in a venture fund that invests in YC batches.
Do you own YC startup equity if you buy RVII? No. You own shares of a fund that owns the startups. Robinhood Ventures DE, LLC controls the positions, sets the marks, and collects a 2% management fee plus 20% of realized gains before anything reaches you.
Do you need to be accredited? Not for RVII or Reg CF platforms. Anyone with a brokerage account can buy RVII on the NYSE, and Reg CF has no income or net worth floor. Syndicates and secondaries still require accreditation, meaning $200,000 in annual income or $1 million in net worth excluding your home.
Can you invest in Y Combinator startups directly?
No, not as an individual retail investor, and this is the part most articles get wrong. Y Combinator is a private accelerator that invests its own capital. It doesn’t sell shares in itself, doesn’t run a public fund open to retail, and won’t take small outside checks into its batches.
YC’s standard deal puts $125,000 into each accepted company for 7% equity, plus a $375,000 uncapped SAFE with a most favored nation clause. That is $500,000 per company, all from YC. The accelerator admits roughly 150 to 200 companies per batch across four batches a year, out of more than 10,000 applications, which puts the acceptance rate near 1%.
That selectivity is the whole product. Nobody at RVII is picking winners inside the portfolio, because the near-equal weighting means the fund treats YC’s admissions decision as the selection mechanism.
The only ways an outsider has historically bought into that pipeline were writing angel checks into individual YC alumni at demo day, joining a syndicate, or committing capital as a limited partner in a fund with YC access. All three required money, connections, or both. RVII is the first version that requires neither, which is exactly why the search volume spiked.
What is Robinhood Ventures Fund II?
RVII is a closed-end business development company registered under the Investment Company Act of 1940, holding roughly 80 early-stage private companies that are current YC participants, YC alumni companies, or startups founded by a YC alum. The BDC wrapper is not a branding choice. It is the only structure the SEC permits for a retail-accessible fund holding mostly illiquid private securities.
The portfolio is close to mechanical. Of the 80 holdings, 78 sit at a standard weight near 1.12%. The single overweight is Tasklet, a cloud agent operating system, at 4.50%. Cash and equivalents make up 7.39%, well below Fund I’s 19.78% cash drag. By sector it is a technology fund with a defense tail: 64.31% technology across 55 companies, then industrials at 8.96% including Tenet Industries’ strike drones and Apollo Atomics’ compact reactors, financial services at 7.84%, and healthcare at 6.72% including CellType’s AI drug discovery work.
Goldman Sachs led the offering, with Citigroup, J.P. Morgan, UBS, and Wells Fargo as joint bookrunners. The SEC declared the registration statement effective on August 12, 2026, one day before the listing. Underwriters hold a 30-day option on an additional 1,200,000 shares, which would push the fund to $255.5 million.
The contrast with Fund I matters. RVI concentrated roughly 73% of its NAV in five late-stage giants: SpaceX, OpenAI, Anthropic, Stripe, and Databricks. Those were companies with real secondary-market price discovery and visible IPO paths. RVII’s holdings are years from any exit, which means their marks are estimates, and they stay estimates for a long time.
What RVII actually costs you
RVII charges a 2.00% annual base management fee on net assets plus a 20% incentive fee on realized capital gains, which regulatory filings translate to estimated total annual expenses of roughly 4.18%. That is a hedge fund fee stack on a product sold through a retail app.
Worth noting what changed between funds. RVI charged the 2% management fee with no performance fee at all. Fund II added the carry. Robinhood tested the concept without it, found demand, and priced the sequel higher.
Run the arithmetic before you decide the fee is abstract. At 4.18% in annual expenses, a $10,000 position gives up about $418 in year one and roughly $2,300 over five years, even if the fund’s value never moves. The portfolio has to compound meaningfully just to keep you level. Venture math can support that, since a single 100x outcome inside an 80-company basket covers a lot of drag. The catch is timing. Early-stage returns arrive in year seven or eight. The fee arrives every quarter.
The fund reportedly borrows against the portfolio too, adding roughly 67% additional exposure on equity. That figure hasn’t been independently confirmed in the filings, but if it holds it amplifies results in both directions. Compare the whole package to the 2.90% net expense ratio on Cathie Wood’s ARK Venture Fund, itself widely criticized as expensive, and RVII sits at the top of the retail private-markets cost curve.
None of this makes the fund a bad product. It makes it an expensive one, and the distinction matters because most early-stage outcomes aren’t clean IPOs. A large share of YC companies exit through acquisition or an acquihire, where the payout structure decides who actually gets paid, and the incentive fee applies to whatever realized gains come out of those deals.
The premium is the part nobody prices in
The single biggest risk in RVII is not the startups. It is the gap between what the shares trade for and what the portfolio is worth, and RVI already ran that experiment in public.
Closed-end funds have a fixed share count and no creation or redemption mechanism, which is what keeps an ETF anchored to its holdings. With no arbitrage, the price is simply whatever the marginal buyer will pay. When enthusiasm outruns the float, you get RVI at $57.02 against a NAV in the mid-twenties. When the story fades, you get NAV or below. Most closed-end funds trade at a discount.
The trigger for RVI’s unwind was specific and predictable. Its thesis was scarcity: the only liquid path to SpaceX. Then SpaceX listed on Nasdaq on June 12 and closed its first day up 19% at a $2 trillion market cap. Once anyone could buy the largest holding directly, the wrapper stopped being special. RVI bled premium every week after that, bottoming at $24.81 in late July before bouncing to $28.64 on August 12, the day before RVII listed. It moved on narrative, not on the underlying companies.
RVII inherits the same structure with a different starting point. It opened below its offer price rather than above it, which is a healthier entry than the alternative and also a signal that the RVI crowd learned something. The rule that survives both funds: the premium you pay at entry matters more than the portfolio you buy. That’s the whole lesson.
Five routes into YC-backed startups, compared
The right route depends on two things: whether you’re accredited, and whether you want a diversified basket or specific companies. Here’s how the five paths stack up.
| Route | Minimum | Accreditation | Cost | Best for |
|---|---|---|---|---|
| RVII (NYSE) | 1 share, about $25 | Not required | ~4.18% a year | Diversified YC exposure with daily liquidity |
| Reg CF platforms | $100 | Not required | Platform fee, no carry | Backing one company you actually understand |
| Interval funds (ARKVX) | $500 | Not required | 2.90% net | Broad private exposure beyond YC |
| Syndicates | $2,500 to $25,000 | Required | Typically 20% carry | Deal-by-deal picking with real diligence |
| Secondaries | $5,000 and up | Required | Transaction fees plus spread | Buying a named later-stage YC alum |
Two of those five are open to everyone. RVII takes any brokerage account. Regulation Crowdfunding platforms including Wefunder and StartEngine let non-accredited investors buy equity directly, sometimes for as little as $100, with a company able to raise up to $5 million per 12-month period. Your own cap is 5% or 10% of the greater of your income or net worth depending on whether both figures clear $124,000, and that limit applies across all platforms combined, not per site.
The trade-off is real. Reg CF gives you direct equity in a company you chose, with no management fee skimming the position, but a YC company raising on Wefunder usually isn’t the one that got the hot term sheet. RVII gives you the batch, marks and all, for 4.18% a year. Pick your problem.
Syndicates and secondaries sit behind the accreditation wall, which the SEC defines as $200,000 in annual income, $300,000 jointly, or $1 million in net worth excluding your primary residence. AngelList and FundersClub syndicates let accredited investors write $2,500 to $25,000 checks into specific deals, typically for 20% carry and no annual management fee. Secondary marketplaces including Forge and EquityZen sell existing shares in later-stage YC alumni, which is how most people get a named position in a company like a business already trading on real revenue multiples rather than a seed-stage mark.
How to buy RVII, step by step
RVII trades like any NYSE-listed stock, so no Robinhood account and no accreditation is needed. The share-request window inside the Robinhood app closed on August 12, one day before listing, and that path is gone until a future offering.
- Open any brokerage account that trades NYSE-listed securities. Fidelity, Schwab, Robinhood, and Interactive Brokers all work.
- Search the ticker RVII. Confirm you are looking at Robinhood Ventures Fund II and not RVI, which is a different fund with different holdings.
- Check the current price against the most recently reported NAV before entering. If NAV has not been disclosed yet, the $25.00 offer price is your only reference point.
- Use a limit order. Closed-end funds on light volume can move fast, and market orders in the first weeks of a listing are how people accidentally pay a premium.
- Size the position like venture, not like an index fund. This is a speculative holding, and the prospectus says so in those words.
What retail access signals for founders
For anyone building a company, the interesting part isn’t the ticker. It’s that public markets now want exposure to seed-stage risk badly enough to buy it at a 4.18% expense ratio, sight unseen, on the strength of Y Combinator’s brand. Goldman Sachs underwrote that bet. The NYSE listed it.
That has second-order effects on how startups get funded. Capital is chasing earlier, which historically compresses seed valuations upward and makes the next round harder to clear, a dynamic anyone who has lived through a down round understands. It also puts quarterly mark-to-market pressure on private companies that used to be able to stay quiet between rounds. When your Series A investor’s investor is a retail shareholder watching a ticker, the reporting expectations change.
The YC brand premium is now literally priced. Robinhood built a $225.5 million product whose entire selection logic is “these companies got into Y Combinator,” which means an admissions decision made by a handful of partners in Mountain View is being underwritten as an investment signal by the NYSE. That is a strong argument for applying, and a warning about how crowded the seed stage has become. It sits alongside other structures pulling non-traditional capital onto cap tables, including athlete investing collectives and the rise of mega-round private valuations that stay private for a decade.
Founders raising right now should also read the fee structure as market intelligence. Investors are willing to pay 2-and-20 for early-stage access, which tells you what your equity is worth to people who will never meet you. That is useful context when you are on the other side of the table reading the signals in a pitch meeting.
Should you buy RVII?
This is not investment advice, and the honest answer is that it depends on four questions you can answer yourself before you place an order.
What are you paying relative to NAV? This is the one that decided RVI’s outcome. If RVII trades meaningfully above its reported net asset value, you are buying sentiment, and sentiment mean-reverts. Opening at $22.50 was arguably the best thing that could have happened to buyers.
Can you hold for eight years? Early-stage venture returns cluster far out. If you need the money in three years, a fund whose holdings are years from any exit is the wrong instrument, regardless of price.
Do you believe the marks? RVII’s positions are early-stage and thinly traded, which means NAV is an estimate produced by the same firm collecting the fee. That is not an accusation, it is a structural conflict worth naming.
Is 4.18% survivable in your model? Assume the basket returns 12% annually. After fees you keep roughly 8%. Decide whether the YC access is worth a third of your return before you decide whether the startups are good.
If those four answers hold up, RVII is a legitimate way to own a slice of the most selective accelerator in tech for the price of lunch. If they do not, the Reg CF route puts direct equity in your name for $100 and no annual drag. The worst outcome is buying a premium because a ticker made venture feel accessible. RVI’s chart is what that looks like from the other side.
